Exclusion of both insulin-treated patients and/or those taking GLP-1 analogues made no difference to the significance of any of the results reported, with the exception that serum-PON-1 activity was no longer significantly different between T2DM and controls. The gene discussed is PON1; the disease is type 2 diabetes mellitus.